全文获取类型
收费全文 | 464篇 |
免费 | 59篇 |
国内免费 | 14篇 |
专业分类
妇产科学 | 3篇 |
基础医学 | 7篇 |
临床医学 | 17篇 |
内科学 | 52篇 |
皮肤病学 | 2篇 |
特种医学 | 4篇 |
外科学 | 70篇 |
综合类 | 23篇 |
预防医学 | 5篇 |
药学 | 51篇 |
1篇 | |
中国医学 | 2篇 |
肿瘤学 | 300篇 |
出版年
2023年 | 6篇 |
2022年 | 27篇 |
2021年 | 23篇 |
2020年 | 34篇 |
2019年 | 23篇 |
2018年 | 25篇 |
2017年 | 32篇 |
2016年 | 16篇 |
2015年 | 25篇 |
2014年 | 59篇 |
2013年 | 49篇 |
2012年 | 30篇 |
2011年 | 38篇 |
2010年 | 16篇 |
2009年 | 40篇 |
2008年 | 29篇 |
2007年 | 20篇 |
2006年 | 19篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 3篇 |
2002年 | 3篇 |
2001年 | 6篇 |
2000年 | 1篇 |
排序方式: 共有537条查询结果,搜索用时 15 毫秒
491.
《Current medical research and opinion》2013,29(4):405-414
Abstract
Background:
Trastuzumab emtansine (T-DM1), a novel drug developed for the treatment of HER2-positive breast cancer, is a human epidermal growth factor receptor (HER2) targeted antibody drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). It has been shown that, in preclinical studies, it has anti-tumor activity in trastuzumab refractory cancer cells. In this review, we aim to show the clinical data about trastuzumab-DM1 (T-DM1) therapy and to discuss the therapy advantages for the management of patients with HER2-positive breast cancer. 相似文献492.
《Current medical research and opinion》2013,29(8):1015-1024
Abstract
Background:
Trastuzumab, an anti-HER2 humanized monoclonal antibody, is the standard treatment for both early and metastatic HER2-positive breast cancer. In addition to other chemotherapeutic agents, trastuzumab significantly improves response rate and survival in HER2-positive early and metastatic breast cancer. Although it is well known that trastuzumab therapy is closely associated with both symptomatic and asymptomatic cardiotoxicity, less is known about novel HER2-targeted therapies. The aim of this review is to discuss the cardiac safety data from recent studies of novel anti-HER2 drugs other than trastuzumab. 相似文献493.
Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy 总被引:7,自引:0,他引:7
Becker JC Muller-Tidow C Serve H Domschke W Pohle T 《World journal of gastroenterology : WJG》2006,12(21):3297-3305
Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor family participate in several steps of tumor formation including proliferation and metastatic spread. Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy. Only preliminary data exist, however, on the use of the currently clinically available drugs such as trastuzumab, cetuximab, bevacizumab, gefitinib, erlotinib, and imatinib in the setting of gastric cancer. Preclinical data suggest a potential benefit of their use, especially in combination with "conventional" cytostatic therapy. This review summarizes the current knowledge about their use in cancer therapy as well as new approaches and drugs to optimize treatment success. 相似文献
494.
495.
Burris HA Tibbitts J Holden SN Sliwkowski MX Lewis Phillips GD 《Clinical breast cancer》2011,11(5):275-282
Increased understanding of the molecular mechanisms of tumorigenesis has led to the development of novel agents that target tumor cells with minimal effects on normal cells. The success of this approach is exemplified by the development of monoclonal antibodies directed toward antigens expressed selectively by tumor cells. The conjugation of these monoclonal antibodies with potent cytotoxic drugs has the potential to further improve efficacy while retaining a favorable safety profile. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) currently in clinical development. It combines the humanized antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2) receptor on cancer cells, and the potent antimicrotubule agent DM1 using a unique highly stable linker. When T-DM1 binds to HER2, a proportion of the receptors are thought to be internalized by the process of receptor endocytosis, followed by the intracellular release of an active form of DM1, which in turn kills the tumor cell. This review presents the rationale for the development of T-DM1 and summarizes the preclinical and clinical data for this novel agent for the treatment of breast cancer. 相似文献
496.
胃癌是全世界常见的消化系统恶性肿瘤之一,是我国第二大肿瘤,5年生存率不足20%。近年来,肿瘤的分子分型与分子靶向治疗方兴未艾,在肺癌、乳腺癌、大肠癌等肿瘤中已初见成效,用于临床治疗指导,疗效预测及预后判断。而胃癌的靶向治疗却迟迟未见端倪, 相似文献
497.
498.
499.
Breast cancer is uncommonly diagnosed during pregnancy but when encountered, it poses several clinical conflicts. Managing patients with gestational breast cancer should not be associated with considerable risk of morbidity provided the choice of the right drug in the right time for the right patient. Due to its relative rarity, we lack a standardized approach to manage these patients. Previous reports have suggested that women can be offered treatment strategies similar to those offered in the “non-pregnant” setup. Nevertheless, generalizing treatment decisions is too hard and treatment of these cases should be tailored according to the clinical situation. In order to ensure proper counseling of these patients, there are several key points that need to be addressed. These include timing of chemotherapy administration, the scheduling of agents, and pregnancy monitoring. In this review, we provide some guidance on how to select the chemotherapy regimen and address the feasibility and safety of administering trastuzumab during pregnancy. We also discuss some practical points on monitoring these patients during the course of pregnancy. 相似文献
500.
Goel S Chirgwin J Francis P Stuart-Harris R Dewar J Mileshkin L Snyder R Michael M Koczwara B 《Breast (Edinburgh, Scotland)》2011,20(2):101-110
The management of HER2-positive metastatic breast cancer, a disease renowned for its aggressive natural history, has been revolutionized by the introduction of trastuzumab. Indeed, outcomes for patients with HER2-positive advanced breast cancer are now equivalent to, if not better than, those of their HER2-negative counterparts. Since the pivotal registration trial, a wealth of new clinical data has emerged regarding the use of trastuzumab in a variety of clinical contexts - adding to the evidence but also highlighting areas of uncertainly and debate. These include the optimal partner chemotherapy(ies) to trastuzumab; the effectiveness of combining trastuzumab with endocrine therapy; the benefits of continuing trastuzumab after progression on a trastuzumab-containing regimen; and the role of trastuzumab in locally advanced and inflammatory breast cancer. In this paper we review major clinical trials addressing these questions, clinical recommendations that can be made as a result, and the strength of evidence that supports them. Finally, we identify areas of ongoing uncertainty, and propose recommendations for future research in this field. 相似文献